Internal Medicine, Infectious Disease · Orlando, FL
NPI
1326048208
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3901 E Colonial Dr
Orlando, FL, 32803
Phone (407) 203-5984
Groups this clinician bills Medicare through
Medicare paid, 2024
$10K
268 services
Medicare patients, 2024
44
Average age 65
Drug cost, 2024
$3.7M
3,333 prescriptions
Company payments, 2025
$2,596
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Roberto Ortiz was code 99214 (office e&m - established), 81 times for 37 patients. In total Roberto Ortiz billed 268 services in 22 codes, and Medicare paid $10K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 81 | 37 | $71.80 | $5,816 |
| 36415 Venipuncture Blood Collection | Office | 68 | 31 | $8.52 | $580 |
| 99213 Office E&M - Established | Office | 32 | 21 | $54.58 | $1,746 |
By year: 2022 $15K for 287 services; 2023 $8,597 for 222 services; 2024 $10K for 268 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 68 | 31 | $8.52 | $580 |
Medicare prescription drug claims, 2024
In 2024, the drug Roberto Ortiz prescribed most often to Medicare patients was Dovato (Dolutegravir Sodium/Lamivudine), with 501 prescriptions and refills. In total Roberto Ortiz wrote 3,333 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dovato Dolutegravir Sodium/Lamivudine | 501 | 501 | 48 | $1.5M |
| Rosuvastatin Calcium Generic | 238 | 266 | 31 | $1,038 |
| Lisinopril Generic | 138 | 162 | 16 | $543 |
| Alprazolam Generic | 133 | 133 | 19 | $267 |
| Levothyroxine Sodium Generic | 117 | 135 | 13 | $389 |
| Zolpidem Tartrate Generic | 115 | 123 | 14 | $779 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 96 | 104 | 14 | $404K |
| Cabenuva Cabotegravir/Rilpivirine | 72 | 132 | 14 | $473K |
| Nebivolol Hcl Generic | 70 | 86 | Under 11 | $2,280 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 70 | 72 | 13 | $212 |
| Losartan Potassium Generic | 65 | 69 | 11 | $290 |
| Clopidogrel Clopidogrel Bisulfate | 57 | 64 | Under 11 | $180 |
| Trazodone Hcl Generic | 54 | 54 | Under 11 | $119 |
| Descovy Emtricitabine/Tenofov Alafenam | 50 | 66 | Under 11 | $141K |
| Juluca Dolutegravir/Rilpivirine | 50 | 50 | Under 11 | $180K |
Brand drugs: 1,168 claims; generic drugs: 2,165 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Roberto Ortiz $2,596 ($2,596 in general payments such as food, travel and fees) from 10 companies. The largest payer was ViiV Healthcare Company with $1,029.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 41 | $1,029 |
| Gilead Sciences, Inc. GILD | 24 | $958 |
| Merck Sharp & Dohme LLC MRK | 12 | $301 |
| Theratechnologies Inc. THTX | 5 | $114 |
| Abbvie Inc. ABBV | 2 | $60.04 |
| Napo Pharmaceuticals Inc | 1 | $43.9 |
| Pfizer Inc. PFE | 2 | $31.02 |
| Axsome Therapeutics, Inc. AXSM | 1 | $26.37 |
| Lilly USA, LLC LLY | 1 | $18.76 |
| EMD Serono, Inc. MRK.DE | 1 | $14.08 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.